• About us
• Contact

Advertisement

Organisation › Details

Valneva S.E. (Nasdaq: VALN, Euronext Paris: VLA)

Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various clinical-stage vaccines in development including unique vaccines against Lyme disease and chikungunya. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 490 employees. *

 

	Start	2013-05-28 merged
	Group	Valneva (Group)
	Predecessor	Vivalis S.A.
	Industry	avian (bird) production technology (transgenic)
	Industry 2	vaccine
	Person	Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
	Person 2	Grimaud, Franck (Vivalis 200702 CEO)
	Region	Nantes
	Country	France
	Street	6 rue Alain Bombard Campus Bio-Quest
	City	44800 Saint-Herblain
		Address record changed: 2024-01-05
Basic data	Employees	E: 501 to 1,000 (2022-12-31)
	Currency	EUR
	Annual sales	361,303,000 (revenues, total, consolidated (2022) 2022-12-31)
	Profit	-143,279,000 (2022-12-31)
	Cash	289,430,000 (2022-06-30)
		* Document for »About Section«: Valneva S.E.. (1/9/20). "Press Release: Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Saint-Herblain.
		Record changed: 2024-02-12

Advertisement

More documents for Valneva (Group)

• [1] Valneva S.E.. (11/10/23). "Press Release: Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
• [2] Valneva S.E.. (11/9/23). "Press Release: Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates". Saint Herblain....
• [3] Valneva S.E.. (11/7/23). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint Herblain....
• [4] Valneva S.E.. (10/25/23). "Press Release: Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment". Saint Herblain....
• [5] Valneva S.E.. (9/25/23). "Press Release: Valneva Announces New Ixiaro Supply Contract with the U.S. Government Worth a Minimum of $32 Million". Saint Herblain....
• [6] NorthX Biologics. (7/3/23). "Press Release: NorthX Biologics, a Leading Nordic Development and Manufacturing Organisation Announces Acquisition of a Biologics Manufacturing Unit from Valneva". Matfors....
• [7] Valneva S.E.. (11/17/22). "Press Release: Valneva Appoints Dipal Patel as Chief Commercial Officer". Saint-Herblain....
• [8] Valneva S.E.. (10/4/22). "Press Release: Valneva Announces Closing of Upsized €102.9 Million Global Offering". Saint-Herblain....
• [9] Valneva S.E.. (8/18/22). "Press Release: Valneva Provides Update on Ixiaro Supply Contract with U.S. Department of Defense". Saint-Herblain....
• [10] Valneva S.E.. (8/8/22). "Press Release: Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15". New York, NY & Saint-Herblain....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.